Accurate Education: 

Visual Snow Syndrome

CAM Treatment

Visual Snow Syndrome (VSS) is a recently identified medical condition that as yet evades definitive effective management. In an effort to identify theoretically possible safe alternatives to help those afflicted with this condition, an AI-based query is investigated here for the use of nutraceuticals as part of a complementary and alternative medicines (CAM)-based approach.

There is no direct clinical evidence for anti-inflammatory dietary supplements specifically in the treatment of Visual Snow Syndrome (VSS). However, a theoretical rationale can be constructed based on the known pathophysiology of VSS and the mechanisms of action of certain nutraceuticals studied in other neurological conditions. The following synthesizes what is known.

 

See:  

  

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Visual Snow Syndrome:

CAM Treatment

Guiding Principles

Before initiating any treatment, several foundational steps are essential:

  1. Screen for comorbidities. Over 50% of VSS patients have comorbid migraine (predominantly with aura), and ≥50% have active depression or anxiety. Tinnitus is present in ~52%. These conditions independently worsen disease burden and coping, and treating them may improve overall outcomes.
  2. Identify and eliminate exacerbating factors. Recreational drugs and alcohol worsen VS symptoms in multiple reports. Certain antidepressants (particularly SSRIs/SNRIs) can trigger or worsen visual symptoms. Indoor and fluorescent lighting have a worse effect on symptoms compared with natural outdoor lighting.
  3. Set realistic expectations. No treatment has achieved complete remission in the majority of patients. The goal is cumulative partial benefit across multiple modalities, improved functional capacity, and reduced distress — not cure.

CAM TX for VSS (Part 1)

There is no direct clinical evidence for anti-inflammatory dietary supplements specifically in the treatment of visual snow syndrome (VSS). However, a theoretical rationale can be constructed based on the known pathophysiology of VSS (cortical hyperexcitability, glutamatergic dysregulation, thalamocortical network dysfunction) and the mechanisms of action of certain nutraceuticals studied in other neurological conditions.

The Only Direct VSS Evidence: Vitamins

The largest treatment survey of VSS (400 patients) found that vitamins had the highest therapeutic ratio of any substance class evaluated — meaning that among patients who tried them, vitamins were more likely to help than harm.[1] However, the study did not specify which vitamins were used, most patients reported no change in their VSS course, and the level of evidence is very low (self-reported, uncontrolled survey data). The authors concluded that vitamins “could be beneficial in some patients” but emphasized that no treatment class was effective for the majority.[1]

Nutraceuticals With Theoretical Relevance to VSS Pathophysiology

Given that VSS involves cortical hyperexcitability, glutamatergic dysregulation, and impaired inhibitory feedback, several anti-inflammatory and neuromodulatory supplements have plausible (but unproven) mechanisms of action:[2][3].

(Please note that the nutraceuticals below have been linked to other pages on this website pertinent to the use of these nutraceuticals for chronic pain. While VSS is not a painful condition, the information on these links will provide insights to the use of these nutraceuticals.)

  • Magnesium — Acts as a natural NMDA receptor antagonist and membrane stabilizer, opposing cortical hyperexcitability. Magnesium blocks voltage-gated calcium channels, activates GABA-A receptors, and suppresses excessive glutamatergic transmission. It is well-established in migraine prophylaxis (a condition sharing cortical hyperexcitability with VSS) and has a favorable safety profile. This is arguably the most mechanistically relevant supplement for VSS.[4]
  • Riboflavin (Vitamin B2) — A cofactor for mitochondrial electron transport, riboflavin is recommended for migraine prevention and has neuroprotective properties including reduction of oxidative stress. Given the overlap between migraine and VSS pathophysiology, it may have theoretical relevance.[5]
  • Coenzyme Q10 (CoQ10) — A mitochondrial cofactor and antioxidant that downregulates NF-κB signaling and reduces proinflammatory cytokines (TNF-α, IL-6). In a small RCT in multiple sclerosis, 500 mg/day lowered inflammatory markers and improved fatigue. Its role in mitochondrial energy metabolism could theoretically support neuronal function in hyperexcitable cortical networks.[6]
  • Omega-3 fatty acids (EPA/DHA) — Suppress microglial activation, reduce proinflammatory cytokines (TNF-α, IL-1β, IL-6), and modulate NF-κB expression via Sirt1 pathways. DHA constitutes ~40% of neural phospholipids and is critical for brain membrane integrity. Omega-3s have demonstrated neuroprotective effects in optic nerve and brain injury models. Their anti-neuroinflammatory properties are well-documented, though untested in VSS.[7][8][5]
  • Curcumin — A potent anti-inflammatory that inhibits NF-κB, reduces TNF-α and IL-1β, and promotes M2 (anti-inflammatory) microglial polarization. Bioavailability is a significant limitation unless formulated with piperine or as a phospholipid complex. Hepatotoxicity has been reported in some animal studies.[7][9][6]
  • Resveratrol — Increases SIRT1 levels, exerts anti-inflammatory and anti-apoptotic effects, and promotes synaptogenesis. Evidence is primarily preclinical.[9]
  • Alpha-lipoic Acid — Scavenges reactive oxygen and nitrogen species, enhances glutathione recycling, and reduces proinflammatory cytokines. A small RCT in MS showed increased total antioxidant capacity with 1200 mg/day.[6]

Important Caveats

The critical limitation is that none of these supplements have been studied in VSS patients in any controlled fashion. The pathophysiology of VSS — while involving cortical hyperexcitability — is distinct from the neuroinflammatory and neurodegenerative conditions where these nutraceuticals have been primarily investigated. VSS appears to be more of a network connectivity and sensory gating disorder than a classic neuroinflammatory condition.[2][10] Therefore, extrapolating anti-inflammatory supplement data from conditions like TBI, Alzheimer’s disease, or MS to VSS requires significant caution.

That said, given the lack of effective pharmacotherapy for VSS, the favorable safety profiles of supplements like magnesium, riboflavin, CoQ10, and omega-3 fatty acids, and the shared pathophysiological feature of cortical hyperexcitability with migraine, a trial of these agents is a reasonable low-risk adjunctive strategy — particularly in patients who also have comorbid migraine, where these supplements have established evidence.[11][12]

Supplement

Mechanism Relevant to VSS

Evidence Level for VSS

Safety Considerations

References

Magnesium

NMDA antagonist, membrane stabilizer, reduces cortical hyperexcitability

None specific to VSS; established for migraine

Generally safe; GI side effects at high doses

[1]

Riboflavin (B2)

Mitochondrial cofactor, neuroprotective

None specific to VSS; established for migraine

Very safe

[2]

CoQ10

Mitochondrial support, anti-inflammatory (↓TNF-α, IL-6)

None specific to VSS; small RCT in MS

GI irritability; rare LFT elevation at high doses

[3]

Omega-3 (EPA/DHA)

Anti-neuroinflammatory, membrane integrity, ↓NF-κB

None specific to VSS

Generally safe; mild GI effects

[4], [5]

Curcumin

↓NF-κB, ↓TNF-α/IL-1β, promotes M2 microglial polarization

None specific to VSS; preclinical neuro data

Bioavailability issues; potential hepatotoxicity

[3], [5], [6]

Vitamins (unspecified)

Various

Highest therapeutic ratio in 400-patient VSS survey

Generally safe

[7]

 

CAM TX for VSS (Part 2) – Dosing

The following summarizes the evidence-based dosing regimens for magnesium, riboflavin, and CoQ10 as used in migraine prophylaxis — the condition sharing cortical hyperexcitability with VSS and the basis for extrapolating these regimens.

Magnesium

The recommended dose is 400–600 mg/day of elemental magnesium, taken once daily or in divided doses.[1][2] The Canadian Headache Society strongly endorses magnesium for migraine prevention, and it carries Level B evidence (probably effective) based on multiple RCTs.[2][3]

Key dosing and formulation considerations:

Formulation matters significantly. Organic salts (citrate, glycinate, malate, taurate) have substantially better bioavailability than inorganic salts (oxide, carbonate). Magnesium oxide — the most commonly prescribed form — actually has among the lowest bioavailability. For neurological applications specifically, magnesium acetyl taurate demonstrated the highest brain tissue concentrations and most rapid absorption in preclinical studies, while magnesium L-threonate also shows enhanced BBB penetration. Magnesium citrate is a reasonable, widely available option with good overall bioavailability.[4][5][6][7][8]

Start at 200 mg/day and titrate up over 1–2 weeks to minimize GI side effects (diarrhea is the primary dose-limiting adverse effect).[3][9]

Toxicity risk is negligible at recommended doses in patients with normal renal function; toxicity has been associated with doses >5,000 mg/day. Renal impairment increases risk and requires dose adjustment or avoidance.[3]

An adequate trial requires at least 12 weeks — most RCTs demonstrating benefit used a 12-week treatment period.[3][9]

 

Riboflavin (Vitamin B2)

The standard dose is 400 mg once daily (or 200 mg twice daily).[2][10] This carries Level B evidence for migraine prophylaxis. A meta-analysis of 9 trials (n=673) confirmed that 400 mg/day for 3 months significantly reduced migraine days, frequency, duration, and pain scores.[10]

Key considerations:

Exceptionally safe. Riboflavin is water-soluble, and intestinal absorption saturates at approximately 25–30 mg per dose — excess is excreted renally. This means that while 400 mg is the studied dose, only a fraction is absorbed at any given time; splitting into divided doses (e.g., 200 mg BID) may improve total absorption.[11]

Adverse effects are minimal: diarrhea, polyuria, and bright yellow urine discoloration (harmless) are the only reported side effects, even at doses up to 400 mg/day. No toxicity concerns exist at this dose range.[12][13][14]

Lower doses (50 mg/day) have not shown efficacy. The 200 mg/day dose may be sufficient in some patients, but 400 mg/day is the most consistently studied effective dose.[15]

Allow a minimum of 3 months for therapeutic effect; the landmark Schoenen trial showed 59% of patients achieved ≥50% reduction in migraine attacks at 3 months.[12]

Coenzyme Q10 (Ubidecarenone)

The recommended dose is 100–400 mg/day, with 300 mg once daily being the most commonly cited regimen.[2][1] CoQ10 carries Level C evidence (possibly effective) for migraine prophylaxis.[2] Meta-analyses have shown a mean reduction of approximately 1.5–1.9 migraine attacks per month and reduced headache duration, though results across systematic reviews are inconsistent.[16][17][3]

Key considerations:

A dose-response meta-analysis found benefit across the 100–400 mg/day range, with most positive trials using 300 mg/day.[18][1]

CoQ10 is lipophilic — take with a fat-containing meal to enhance absorption.

Side effects are generally mild (GI discomfort); rare reports of elevated LFTs at high doses.

Allow at least 3 months for assessment of efficacy, consistent with the trial durations in the evidence base.[16]

 

Practical Combination Approach

An open-label study of 113 episodic migraine patients using a fixed combination of magnesium, riboflavin, CoQ10, feverfew, and andrographis paniculata found that 56.6% were responders (≥50% reduction in monthly migraine days) at 3 months, with significant improvements in disability scores and no safety concerns.[19] This supports the feasibility and tolerability of combining these supplements.

Supplement

Dose

Formulation Notes

Onset of Effect

Level of Evidence (Migraine)

Key Side Effects

References

Magnesium

400–600 mg/day elemental

Citrate, glycinate, or taurate preferred over oxide; threonate/acetyl taurate for CNS targeting

12 weeks minimum

Level B

Diarrhea (dose-dependent); avoid in renal impairment

[1], [2], [3]

Riboflavin (B2)

400 mg/day (or 200 mg BID)

Water-soluble; absorption saturates ~25–30 mg/dose; divided dosing may improve uptake

3 months minimum

Level B

Yellow urine, rare diarrhea/polyuria; no toxicity

[2], [4], [5]

CoQ10

300 mg/day (range 100–400)

Lipophilic; take with fatty meal

3 months minimum

Level C

Mild GI;

rare LFT elevation

[2], [6], [7]

 

It bears repeating that all of this dosing evidence derives from migraine prophylaxis trials, not VSS-specific studies. The rationale for use in VSS is based on the shared mechanism of cortical hyperexcitability. A minimum 3-month trial of all three supplements simultaneously is reasonable, with reassessment of symptom burden at that point.

 

 

 References for CAM Treatment, Part 1

  1. Evaluation of Treatment Response and Symptom Progression in 400 Patients With Visual Snow Syndrome. Puledda F, Vandenbussche N, Moreno-Ajona D, et al. The British Journal of Ophthalmology. 2022;106(9):1318-1324. doi:10.1136/bjophthalmol-2020-318653.
  2. Visual Snow vs. Migraine Aura: Debate Summary and Novel Insights Into the Syndrome. Braca S, Santoro V, Sebastianelli G, et al. Cephalalgia : An International Journal of Headache. 2025;45(9):3331024251365908. doi:10.1177/03331024251365908.
  3. Visual Snow Syndrome: Recent Advances in Understanding the Pathophysiology and Potential Treatment Approaches. Aeschlimann SA, Klein A, Schankin CJ. Current Opinion in Neurology. 2024;37(3):283-288. doi:10.1097/WCO.0000000000001258.
  4. The Impact of Chronic Magnesium Deficiency on Excitable Tissues-Translational Aspects. Stanojević M, Djuricic N, Parezanovic M, et al. Biological Trace Element Research. 2025;203(2):707-728. doi:10.1007/s12011-024-04216-2.
  5. Supplement and Nutraceutical Therapy in Traumatic Brain Injury. Lucke-Wold B, Zasler ND, Ruchika F, et al. Nutritional Neuroscience. 2025;28(6):709-743. doi:10.1080/1028415X.2024.2404782.
  6. Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review. Evans E, Piccio L, Cross AH. JAMA Neurology. 2018;75(8):1013-1021. doi:10.1001/jamaneurol.2018.0611.
  7. Connection between Systemic Inflammation and Neuroinflammation Underlies Neuroprotective Mechanism of Several Phytochemicals in Neurodegenerative Diseases. Wang J, Song Y, Chen Z, Leng SX. Oxidative Medicine and Cellular Longevity. 2018;2018:1972714. doi:10.1155/2018/1972714.
  8. Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids in a Rat Model of Anterior Ischemic Optic Neuropathy. Georgiou T, Wen YT, Chang CH, et al. Investigative Ophthalmology & Visual Science. 2017;58(3):1603-1611. doi:10.1167/iovs.16-20979.
  9. The Role of Neuro-Supportive Substances of Natural Origin in Neurological Conditions-a Literature-Based Formulators’ Perspective. van Brummelen R, van Brummelen AC. Frontiers in Neurology. 2025;16:1647092. doi:10.3389/fneur.2025.1647092.
  10. Visual Snow Syndrome, the Spectrum of Perceptual Disorders, and Migraine as a Common Risk Factor: A Narrative Review. Klein A, Schankin CJ. Headache. 2021;61(9):1306-1313. doi:10.1111/head.14213.
  11. Diagnostic and Management Strategies of Visual Snow Syndrome: Current Perspectives. Ayesha A, Riehle C, Leishangthem L. Eye and Brain. 2025;17:1-11. doi:10.2147/EB.S418923.
  12. Treatment Effects and Comorbid Diseases in 58 Patients With Visual Snow. van Dongen RM, Waaijer LC, Onderwater GLJ, Ferrari MD, Terwindt GM. Neurology. 2019;93(4):e398-e403. doi:10.1212/WNL.0000000000007825.

 

References for CAM Treatment, Part 2

  1. Migraine Headache Prophylaxis. Moreland P, Gaffney B, Lanham JS. American Family Physician. 2025;111(5):443-450.
  2. Migraine. Dodick DW. Lancet (London, England). 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1.
  3. Management of Headache (2023). Jane Abanes PhD DNP MSN/Ed PMHCNS PMHNP-BC RN, Natasha M. Antonovich PharmD BCPS, Andrew C. Buelt DO, et al. Department of Veterans Affairs.
  4. Magnesium Disorders. Touyz RM, de Baaij JHF, Hoenderop JGJ. The New England Journal of Medicine. 2024;390(21):1998-2009. doi:10.1056/NEJMra1510603.
  5. Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best?. Uysal N, Kizildag S, Yuce Z, et al. Biological Trace Element Research. 2019;187(1):128-136. doi:10.1007/s12011-018-1351-9.
  6. Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation. Kumar A, Mehan S, Tiwari A, et al. Current Pharmaceutical Design. 2024;30(39):3074-3107. doi:10.2174/0113816128321466240816075041.
  7. A Mini Review on the Various Facets Effecting Brain Delivery of Magnesium and Its Role in Neurological Disorders. Mathew AA, Panonnummal R. Biological Trace Element Research. 2023;201(9):4238-4253. doi:10.1007/s12011-022-03517-8.
  8. Chronic Organic Magnesium Supplementation Enhances Tissue-Specific Bioavailability and Functional Capacity in Rats: A Focus on Brain, Muscle, and Vascular Health. Koc B, Hosgorler F, Kandis S, et al. Biological Trace Element Research. 2025;:10.1007/s12011-025-04678-y. doi:10.1007/s12011-025-04678-y.
  9. Magnesium Supplementation for Migraine Prophylaxis. Rodriguez JP, Quarteroni E, Varela LB, Escobar Liquitay CM, Garegnani LI. The Cochrane Database of Systematic Reviews. 2025;11:CD016307. doi:10.1002/14651858.CD016307.
  10. Effect of Vitamin B2 Supplementation on Migraine Prophylaxis: A Systematic Review and Meta-Analysis. Chen YS, Lee HF, Tsai CH, et al. Nutritional Neuroscience. 2022;25(9):1801-1812. doi:10.1080/1028415X.2021.1904542.
  11. Riboflavin Supplements for Blood Pressure Lowering in Adults. Bradbury KE, Coffey S, Earle N, Ni Mhurchu C, Jull AB. The Cochrane Database of Systematic Reviews. 2025;10:CD015464. doi:10.1002/14651858.CD015464.pub2.
  12. Effectiveness of High-Dose Riboflavin in Migraine Prophylaxis. A Randomized Controlled Trial. Schoenen J, Jacquy J, Lenaerts M. Neurology. 1998;50(2):466-70. doi:10.1212/wnl.50.2.466.
  13. Riboflavin Transporter Deficiency. Cali E, Dominik N, Manole A, et al. GeneReviews® [Internet]. Updated 2021 Apr 8.
  14. Medicinal Benefits, Biological, and Nanoencapsulation Functions of Riboflavin With Its Toxicity Profile: A Narrative Review. Lee TY, Farah N, Chin VK, et al. Nutrition Research (New York, N.Y.). 2023;119:1-20. doi:10.1016/j.nutres.2023.08.010.
  15. Vitamin Supplementation as Possible Prophylactic Treatment against Migraine with Aura and Menstrual Migraine. Shaik MM, Gan SH. BioMed Research International. 2015;2015:469529. doi:10.1155/2015/469529.
  16. Coenzyme Q10 Supplementation for Prophylaxis in Adult Patients With Migraine-a Meta-Analysis. Sazali S, Badrin S, Norhayati MN, Idris NS. BMJ Open. 2021;11(1):e039358. doi:10.1136/bmjopen-2020-039358.
  17. Effect of Coenzyme Q10 Supplementation on Clinical Features of Migraine: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Parohan M, Sarraf P, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Nutritional Neuroscience. 2020;23(11):868-875. doi:10.1080/1028415X.2019.1572940.
  18. Effects of Selected Dietary Supplements on Migraine Prophylaxis: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Talandashti MK, Shahinfar H, Delgarm P, Jazayeri S. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2025;46(2):651-670. doi:10.1007/s10072-024-07794-0.
  19. Open Label Prospective Experience of Supplementation With a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. Vikelis M, Dermitzakis EV, Vlachos GS, et al. Journal of Clinical Medicine. 2020;10(1):E67. doi:10.3390/jcm10010067.

 

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.